Why the study?
Prospective studies evaluating persistence to nonvitamin K antagonist oral anticoagulants in atrial fibrillation were needed to improve understanding of drug discontinuation.
In patients with newly diagnosed atrial fibrillation, 2-year persistence on dabigatran is approximately 71%, with the highest risk of discontinuation occurring in the first 6 months, highlighting a critical window for clinical intervention.
No takes yet. Share an insight, caveat, or question.
Dabigatran persistence remains suboptimal with highest early dropout; leaves open targeted adherence interventions in new AF.
Paquette et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: